Grill Joshua D, Apostolova Liana G, Bullain Szofia, Burns Jeffrey M, Cox Chelsea G, Dick Malcolm, Hartley Dean, Kawas Claudia, Kremen Sarah, Lingler Jennifer, Lopez Oscar L, Mapstone Mark, Pierce Aimee, Rabinovici Gil, Roberts J Scott, Sajjadi Seyed Ahmad, Teng Edmond, Karlawish Jason
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA.
Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA.
Alzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y.
Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling.
We convened a workgroup to formulate recommendations for clinicians providing care to MCI patients.
Clinicians should use the MCI diagnosis to validate patient and family concerns and educate them that the patient's cognitive impairment is not normal for his or her age and education level. The MCI diagnosis should not be used to avoid delivering a diagnosis of dementia. For patients who meet Appropriate Use Criteria after standard-of-care clinical workup, amyloid imaging may position specialists to offer more information about etiology and prognosis. Clinicians must set appropriate expectations, including ensuring that patients and families understand the limitations of amyloid imaging. Communication of negative results should include that patients remain at elevated risk for dementia and that negative scans do not indicate a specific diagnosis or signify brain health. Positive amyloid imaging results should elicit further monitoring and conversations about appropriate advance planning. Clinicians should offer written summaries, including referral to appropriate social services.
In patients with MCI, there is a need to devote considerable time and attention to patient education and shared decision-making. Amyloid imaging may be a tool to aid clinicians. Careful management of patient expectations and communication of scan results will be critical to the appropriate use of amyloid imaging information.
轻度认知障碍(MCI)的病因和预后尚不明确,临床医生与患者及其家属讨论时可能颇具挑战。淀粉样蛋白成像有助于专家确定MCI的病因和预后,但也带来了与疾病标签相关的新挑战。
我们召集了一个工作组,为诊治MCI患者的临床医生制定建议。
临床医生应利用MCI诊断来确认患者及其家属的担忧,并告知他们患者的认知障碍对于其年龄和教育水平而言并非正常现象。MCI诊断不应被用于避免做出痴呆症的诊断。对于在标准临床检查后符合合理使用标准的患者,淀粉样蛋白成像可能使专家能够提供更多关于病因和预后的信息。临床医生必须设定适当的预期,包括确保患者及其家属了解淀粉样蛋白成像的局限性。阴性结果的告知应包括患者患痴呆症的风险仍然较高,以及阴性扫描结果并不代表特定诊断或表明脑部健康。淀粉样蛋白成像阳性结果应引发进一步监测以及关于适当预先规划的讨论。临床医生应提供书面总结,包括转介至适当的社会服务机构。
对于MCI患者,需要投入大量时间并关注患者教育和共同决策。淀粉样蛋白成像可能是帮助临床医生的一种工具。谨慎管理患者预期并传达扫描结果对于合理使用淀粉样蛋白成像信息至关重要。